US4644056A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preparing a solution of lactic or colostric immunoglobulins or both and use thereof
Assignee: GalaGen Inc
•
Filing: 1985-09-03
•
Granted: 1987-02-17
•
Expires: 2005-09-03
Abstract
Abstract A method of preparing a solution of lactic or colostric immunoglobulins or both by processing milk or colostrum or both accompanied by precipitation of the caseins, characterized in that milk or colostrum or both are acidified to a pH of 4.0-5.5, subjected to cross-flow filtration in a filtration unit with a mean pore size of 0.1-1.2 mu m, and the low-molecular components removed by means of further cross-flow filtration in another filtration unit with a limit of separation of 5 000-80 000 daltons, as well as an agent for treating bacterial and viral infections that consists of a solution obtained by means of said method.
Inventors
- 👤 Norbert Kothe
- 👤 Herbert Dichtelmuller
- 👤 Wolfgang Stephan
- 👤 Bertram Eichentopf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:16
CPC Classifications
A; A23; A23C; A23C9/00; A23C9/14; A23C9/142; A23C9/1422; A23J; A23J1/00; A23J1/20; A23J1/202; A61; A61P; A61P31/00; A61P31/04; A61P31/12; A23C2210/00; A23C2210/20; A23C2210/206; B; B01; B01D; B01D2319/00; B01D2319/06; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/832; Y10S530/863
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
80 words
In the preparation of a solution of lactic or colostric immunoglobulins by processing a lactic and/or colostric milk and precipitating the caseins, the improvement which comprises acidifying the milk to a pH of 4.0-5.5, subjecting the milk to cross-flow filtration in a filtration unit with a mean pore size of 0.1-1.2 μm, and subjecting the filtrate to a further cross-flow filtration in another filtration unit with a limit of separation of 5,000-80,000 daltons, thereby to separate the low-molecular components therefrom.
Claim 2
Dependent Claim
80 words
In the preparation of a solution of lactic or colostric immunoglobulins by processing a lactic and/or colostric milk and precipitating the caseins, the improvement which comprises acidifying the milk to a pH of 4.0-5.5, subjecting the milk to cross-flow filtration in a filtration unit with a mean pore size of 0.1-1.2 μm, and subjecting the filtrate to a further cross-flow filtration in another filtration unit with a limit of separation of 5,000-80,000 daltons, thereby to separate the low-molecular components therefrom.
Claim 3
Dependent Claim
15 words
The method according to claim 1, wherein the colostrum is employed as the starting milk.
Claim 4
Dependent Claim
15 words
The method according to claim 1, wherein the starting material is colostrum from non-hyperimmunized mammals.
Claim 5
Dependent Claim
13 words
The method according to claim 1, wherein the starting milk is human colostrum.
Claim 6
Dependent Claim
21 words
The method according to claim 1, wherein the starting material is colostrum obtained from cows up to 30 hours after calving.
Claim 7
Dependent Claim
21 words
The method according to claim 1, wherein the starting milk is colostrum obtained from cows up to 5 hours after calving.
Claim 8
Dependent Claim
19 words
The method according to claim 1, wherein the milk prior to filtration is diluted with a 0.3-1.5% electrolyte solution.
Claim 9
Dependent Claim
17 words
The method according to claim 1, wherein the starting milk is acidified to a pH of 4.8.
Claim 10
Dependent Claim
23 words
The method according to claim 1, wherein the first filtration is effected with a hollow-fiber cartridge with a pore size of 0.4 μm.
Claim 11
Dependent Claim
24 words
The method according to claim 1, wherein the second filtration is effected with a hollow-fiber cartridge with a limit of separation of 10,000 daltons.
Claim 12
Dependent Claim
24 words
The method according to claim 1, wherein in the second filtration the solution is concentrated to a desired protein content and then filtration sterilized.
Claim 13
Dependent Claim
15 words
A solution for treating bacterial and viral infections produced by the process of claim 1.
References Cited (Backward Citations)
US4018752A
Cited
US4051235A
Cited
DE2813984A1
Cited
GB1573995A
Cited
US4265924A
Cited
US4377569A
Cited
US4490290A
Cited
DE3218348A1
Cited
US4436658A
Cited
EP0085005A1
Cited
US4526715A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-02-16 | 1990-08-18 | 1991-02-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-02-16 | 1994-08-18 | 1995-02-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-02-16 | 1998-08-18 | 1999-02-17 | $7700.00 | Window Closed / Lapsed |